Showing results (121-130 of 134) with videos related to
Sort By:
Pageof 14
Cell Chemical Biology|February 16, 2021
Nuisance compounds in cellular assaysJayme L Dahlin, Douglas S Auld, Ina Rothenaigner, et al.Journal of Pain and Symptom Management|April 11, 2008
A randomized controlled trial testing the efficacy of an HIV/AIDS symptom management manualDean J Wantland, William L Holzemer, Shahnaz Moezzi, et al.Cell Metabolism|August 19, 2022
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptTamer Coskun, Shweta Urva, William C Roell, et al.Nature Chemical Biology|July 22, 2020
Structural insights into probe-dependent positive allosterism of the GLP-1 receptorAna B Bueno, Bingfa Sun, Francis S Willard, et al.Science Advances|June 18, 2025
Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical modelsTito Borner, Allison M Pataro, Sarah A Doebley, et al.Journal of Medicinal Chemistry|March 15, 2021
Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 ReceptorFrancis S Willard, David B Wainscott, Aaron D Showalter, et al.Diabetes, Obesity & Metabolism|January 9, 2026
GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian modelsCaitlin Baumer-Harrison, Danya Aldaghma, Alex D White, et al.JCI Insight|July 31, 2020
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistFrancis S Willard, Jonathan D Douros, Maria Bn Gabe, et al.Nature|January 10, 2020
Activation of the GLP-1 receptor by a non-peptidic agonistPeishen Zhao, Yi-Lynn Liang, Matthew J Belousoff, et al.Endocrinology|September 23, 2017
Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5Thomas B Farb, Marta Adeva, Thomas J Beauchamp, et al.Pageof 14